Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01366378 · ClinicalTrials.gov registry record · Phase 1
Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX
A Phase 1 study of Healthy Adult Subjects, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01366378 is a Phase 1 study of Healthy Adult Subjects that has completed, run by Bausch Health Americas. The registered enrollment target is 18 participants, below the 38-participant average among 3 other Healthy Adult Subjects trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01366378, a Phase 1 study of Healthy Adult Subjects, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This open-label study assesses the single-dose pharmacokinetics of intravenously-administered MNTX in healthy adult male and female subjects in the absence of, and in the presence of, orally-administered cimetidine.
Conditions Studied
Interventions
- DRUG methylnaltrexone
Study Locations (1)
New York
- Progenics Pharmaceuticals, Inc. - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01366378
The ClinicalTrials.gov registry entry for NCT01366378 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38-participant average among 3 other Healthy Adult Subjects trials with a reported enrollment target (53% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adult Subjects appearing as the primary indexed condition, and to 1 intervention - of which methylnaltrexone is the first listed.
NCT01366378 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01366378 about?
NCT01366378 is a clinical study titled "Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX". This open-label study assesses the single-dose pharmacokinetics of intravenously-administered MNTX in healthy adult male and female subjects in the absence of, and in the presence of, orally-administered cimetidine.
What is the current status of trial NCT01366378?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-01. Estimated completion is 2007-02.
What conditions does trial NCT01366378 study?
This clinical trial studies the following conditions: Healthy Adult Subjects.
What interventions are being tested in trial NCT01366378?
The interventions under investigation include: methylnaltrexone (DRUG).
Who is sponsoring clinical trial NCT01366378?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01366378 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.